Evommune

Evommune FCF Yield

The Free Cash Flow Yield of Evommune (EVMN) as of Oct 29, 2026 is -8.97 %. In the previous year, Free Cash Flow Yield was -6.82 % — a change of 31.56% (lower).

FCF Yield

-8.97 %

YoY

31.56%

Last updated:

Free Cash Flow Yield of Evommune is 2025 -8.97 % . Free Cash Flow Yield of Evommune was 2024 -6.82 % . It decreases by 31.56% lower compared to the previous year.

The Evommune FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2023
-3.52 USD
Jan 1, 2024
-6.82 USD
Jan 1, 2025
-8.97 USD
The Evommune FCF Yield history
YEARFCF YieldYoY
-8.97 %+31.56%
-6.82 %+93.71%
-3.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Evommune Stock analysis

What does Evommune do? Evommune Inc generates revenue through its research and development activities focused on inflammatory diseases. The company employs a tissue-based approach using skin as a lens to develop transformative medicines in immunology and dermatology. Its primary products are advanced therapeutic solutions for inflammatory conditions, targeting pharmaceutical companies seeking to accelerate drug development. The firm serves the biotechnology and pharmaceutical sectors with its innovative R&D services. The company's business model centers on providing specialized research services to accelerate medicine development. Evommune, Inc. leverages skin tissue insights to uncover new approaches for immunology and dermatology treatments. Its services are purchased by pharmaceutical firms aiming to enhance their drug development pipelines. The firm's R&D focus on inflammatory diseases positions it as a key partner for companies in the biotech industry. Evommune Inc's revenue streams come from contractual R&D services for pharmaceutical clients. The company's tissue-based methodology for inflammatory disease research is its core offering. It develops and delivers research insights that help clients advance their medicine development in immunology and dermatology. The firm's approach targets the biotechnology sector's need for faster, more effective drug development solutions. Evommune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Evommune stock

Free Cash Flow Yield of Evommune is -8.97 % in 2025.

Free Cash Flow Yield of Evommune changed from -6.82 % to -8.97 %, representing a 31.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Evommune since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Evommune with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Evommune

All Key Metrics — Evommune